Ontology highlight
ABSTRACT: Conclusion
Collectively, these data demonstrate the effectiveness of MSDC-0602 for attenuating NASH in a rodent model and suggest that targeting hepatic MPC2 may be an effective strategy for pharmacologic development. (Hepatology 2017;65:1543-1556).
SUBMITTER: McCommis KS
PROVIDER: S-EPMC5397348 | biostudies-literature | 2017 May
REPOSITORIES: biostudies-literature
McCommis Kyle S KS Hodges Wesley T WT Brunt Elizabeth M EM Nalbantoglu Ilke I McDonald William G WG Holley Christopher C Fujiwara Hideji H Schaffer Jean E JE Colca Jerry R JR Finck Brian N BN
Hepatology (Baltimore, Md.) 20170330 5
Diseases of the liver related to metabolic syndrome have emerged as the most common and undertreated hepatic ailments. The cause of nonalcoholic fatty liver disease is the aberrant accumulation of lipid in hepatocytes, though the mechanisms whereby this leads to hepatocyte dysfunction, death, and hepatic fibrosis are still unclear. Insulin-sensitizing thiazolidinediones have shown efficacy in treating nonalcoholic steatohepatitis (NASH), but their widespread use is constrained by dose-limiting s ...[more]